News

Repeated dosing of ACD856, an investigational therapy for Alzheimer’s disease, was generally safe and well tolerated in healthy adult volunteers, according to data from a now-completed Phase 1 trial. AlzeCure Pharma is developing ACD856 as its lead therapeutic candidate in the company’s NeuroRestore platform, which contains investigational therapies for…

The toxic clumping of amyloid-beta, one of two key proteins implicated in Alzheimer’s disease, causes living human cells to generate heat, which may cause more clumps to form, a study suggests. “Overheating a cell is like frying an egg — as it heats up, the proteins start to clump…

The U.S. Food and Drug Administration (FDA) has agreed to review an application from Eisai seeking accelerated approval of lecanemab (BAN2401), an investigational amyloid-targeting antibody to treat early Alzheimer’s disease in people with confirmed amyloid plaques in the brain. Eisai finished the rolling application a few months ago.

The author of a new book on Alzheimer’s disease is raising questions about whether aging should be more of a concern when it comes to U.S. political leaders. “Age is the biggest risk factor for developing Alzheimer’s disease,” stated a press release from author Lisa Skinner, announcing the…

Posit Science, which produces the BrainHQ app, is collaborating with the YMCA of San Francisco to establish a model community-based program for dementia prevention. Posit Science received a $465,000 grant from the National Institutes of Health to develop the program with the YMCA and input from brain health experts at…

Women in the United States are largely uninformed when it comes to some critical health issues, including their relatively higher risk of developing Alzheimer’s disease as compared to men, according to a comprehensive survey about the state of women’s health. Results of the survey conducted by the Women’s Alzheimer’s Movement…

ALPHA-1062, Alpha Cognition’s investigational oral tablet for mild to moderate Alzheimer’s disease, may be a bioequivalent substitute for the approved therapy Razadyne, according to a pivotal trial with healthy volunteers. The pro-drug therapy — meaning that the medication is metabolized in the body, after administration — showed positive…

Early treatment with crenezumab, an investigational anti-amyloid antibody, failed to significantly slow or prevent cognitive decline in a group of people with a genetic risk for early-onset Alzheimer’s disease, data from a Phase 2 trial show. Numerical differences favoring crenezumab over a placebo were seen across…

A Phase 2 clinical trial will test BMND08, an investigational oral therapy based on a natural psychedelic, in treating depression and anxiety in people with Alzheimer’s disease, its developer, Biomind Labs, reported. The company’s announcement follows the trial’s approval by an institutional review board in Argentina.

Hoth Therapeutics and Washington University have agreed to extend preclinical research into HT-ALZ, Hoth’s experimental therapy for Alzheimer’s disease. Research findings are expected to be helpful in estimating the best dose of HT-ALZ to test in potential clinical trials, according to a company press release. Hoth entered into…